Melissa B. Epperly, Chief Financial Officer at Zentalis Pharmaceuticals, Inc. (ZNTL), sold 15,702 shares at $20.42 ($316K) on 2023-02-13, disclosed to the SEC on 2023-02-14.
Open-market sale of $316k ZNTL by Chief Financial Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $20.42 | 2,624 | $54K | 17.0% |
| 2 | $20.42 | 2,624 | $54K | 17.0% |
| 3 | $19.98 | 5,227 | $104K | 33.0% |
| 4 | $19.98 | 5,227 | $104K | 33.0% |
| Total | $20.13 avg | 15,702 | $316K | 100% |
| Filing → |
| ROIV | SELL | 2026-07-01 | $610K | — | Filing → |
| ROIV | SELL | 2026-03-18 | $1.2M | — | Filing → |
| ZNTL | SELL | 2024-02-12 | $29K | — | Filing → |